| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/26/2002 | WO2001095711A3 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 09/26/2002 | WO2001090159B1 Compositions and methods for delivery of a molecule into a cell |
| 09/26/2002 | WO2001087343A3 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 09/26/2002 | WO2001085093A9 Compounds and methods for modulating cerebral amyloid angiopathy |
| 09/26/2002 | WO2001073002A3 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 09/26/2002 | WO2001034119A9 Inhibitors of crystallization in a solid dispersion |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | WO2001011054A9 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 09/26/2002 | WO2000074634A9 Methods and compositions for modulating cell proliferation and cell death |
| 09/26/2002 | WO2000061112A3 Solubilized pharmaceutical composition for parenteral administration |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | US20020138874 Elongase genes and uses thereof |
| 09/26/2002 | US20020138865 In vitro transfection, storage and transfer of male germ cells for generation of transgenic species & genetic therapies |
| 09/26/2002 | US20020138862 Mice show an increased insulin sensitivity, and resistance to weight gain compared to wild-type mice on same diet; screening for enzyme inhibitors; antiobesity, antidiabetic agents |
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020137941 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 09/26/2002 | US20020137939 Novel guanidinobenzamides |
| 09/26/2002 | US20020137928 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 09/26/2002 | US20020137905 A membrane protein induced by interferons; treating and preventing cancer and viral infection; mediate trans-bilayer movement of membrane phospholipids |
| 09/26/2002 | US20020137884 Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor |
| 09/26/2002 | US20020137801 Administering gossypol; kits to treat patients |
| 09/26/2002 | US20020137800 2-cyclopenten-1-one and its derivatives as inhibitors of the NF-kB factor |
| 09/26/2002 | US20020137798 Treatment of disorders secondary to organic impairments |
| 09/26/2002 | US20020137797 Alpha-Difluoromethylornithine (DFMO) suppresses polyamine levels in the human prostate |
| 09/26/2002 | US20020137792 Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes |
| 09/26/2002 | US20020137782 Amide substituted benzimidazole or benzoxazole; regulating the interaction of vascular cell adhesion molecule-1 and fibronectin with the integrin vascular cell adhesion molecule very late antigen-4 |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137777 Benzothiazole, riluzole, phenylbenzothiazole or lifarizine as blocking agents to limit sodium/calcium exchange in the retinal ganglion cells |
| 09/26/2002 | US20020137769 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
| 09/26/2002 | US20020137761 Treating tolerance or drug addiction; analgesics |
| 09/26/2002 | US20020137755 Tyrosine kinase inhibitors |
| 09/26/2002 | US20020137748 Reducing intestinal toxicity of a noncompetitive thymidylate synthase inhibitor by co-administering a folate derivative without blocking therapy; anticancer, antitumore agents |
| 09/26/2002 | US20020137745 N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease |
| 09/26/2002 | US20020137744 Metalloprotease inhibitors |
| 09/26/2002 | US20020137742 Benzenesulfonamide compounds |
| 09/26/2002 | US20020137740 CRF (corticotropin releasing factor) antagonists; 4-(2-Chloro-4-methoxyphenyl)-5-methyl-2-(N-(5-ethoxy-carbonyl-2 -methoxyphenyl)-N-propylamino)thiazole for example |
| 09/26/2002 | US20020137721 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 09/26/2002 | US20020137691 Supplement collagen and elastic tissues and thicken the dermis; administering a sugar compound converting mucopoly-saccharides; enzyme inhibitor of collangenase/elastase; an amino acid; fat burner, vaso-dilator and chromium picolinate |
| 09/26/2002 | US20020137689 Hypolipidemic agents |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137679 Thrombospondins-1 and -2 are adhesive glycoproteins proteins that are angiogenesis inhibitors; portions of TSP- 1, TSP-2, endostatin, angiostatin, platelet factor 4, or prolactin linked to a portion of cartilage oligoeric matrix protein |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137663 The anti-neoplastic agent ET-743 inhibits trans activation by SXR |
| 09/26/2002 | US20020137210 Method for modifying genetic characteristics of an organism |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137184 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof |
| 09/26/2002 | US20020137182 For obtaining and using a polypeptide other than oncogene BCL-2 that affects programmed vertebrate cell death |
| 09/26/2002 | US20020137155 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher Basidiomycetes mushroom |
| 09/26/2002 | US20020137133 Receptor proteins |
| 09/26/2002 | US20020137127 Culture product; polypeptides |
| 09/26/2002 | US20020137049 Pablo, a polypeptide that interacts with Bcl-xL, and uses related thereto |
| 09/26/2002 | US20020137028 Use of neuronal apoptosis inhibitor protein (naip) |
| 09/26/2002 | US20020136819 Conserved concentrations of cocoa polyphenols by mixing carbohydrate or protein containing ingredients with a polyphenol conserving pretreatment ingredient and then with a cocoa polyphenol |
| 09/26/2002 | US20020136786 Composition and method for smoke detoxification |
| 09/26/2002 | US20020136784 Cyclooxygenase-2 (COX-2); administering a plant extract; nonsteroidal anti-inflammatory agents |
| 09/26/2002 | US20020136775 Aldosterone receptor blockers |
| 09/26/2002 | US20020136744 Sustained release drug dispersion delivery device |
| 09/26/2002 | US20020136731 Targeted therapeutic delivery of vitamin D compounds |
| 09/26/2002 | US20020136719 For biomedical applications, including biological delivery to humans and animals |
| 09/26/2002 | US20020136717 Process for screening chemical compounds for modulating the interaction of an EVH1 domain or a protein having an EVH1 domain with an EVH1 binding domain or a protein having an EVH1 binding domain, and a process for detecting said interaction |
| 09/26/2002 | DE10113366A1 Medicament for treating inflammatory or obstructive respiratory diseases, e.g. asthma or chronic obstructive pulmonary disease, containing synergistic combination of anticholinergic agent and endothelin antagonist |
| 09/26/2002 | DE10112041A1 p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate p-thienylbenzyl amides as agonists of angiotensin- (1-7) receptors, processes for their preparation, their use and pharmaceutical compositions containing them |
| 09/26/2002 | CA2445374A1 Process for producing lactic acid oligomer |
| 09/26/2002 | CA2444526A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2442268A1 Benzimidazol derivatives modulate chemokine receptors |
| 09/26/2002 | CA2441740A1 Dopaminergic neuronal survival-promoting factors and uses thereof |
| 09/26/2002 | CA2441564A1 Production of pancreatic islet cells and delivery of insulin |
| 09/26/2002 | CA2441563A1 Allosteric adenosine receptor modulators |
| 09/26/2002 | CA2441289A1 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal |
| 09/26/2002 | CA2441162A1 Pharmaceutical composition comprising, as an active ingredient, triazaspiro[5.5]undecane derivative |
| 09/26/2002 | CA2441155A1 Methods of treating respiratory conditions |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2440954A1 Phenyl derivatives 3 |
| 09/26/2002 | CA2440749A1 Isolation and purification procedure of vasopeptidase peptide inhibitors |
| 09/26/2002 | CA2440632A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440482A1 Tryptase-inhibitors |
| 09/26/2002 | CA2440475A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2440264A1 Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient |
| 09/26/2002 | CA2440106A1 Substituted benzopyranones as telomerase inhibitors |
| 09/26/2002 | CA2440002A1 Pyrrolidine ester derivatives with oxytocin modulating activity |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2439530A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 09/26/2002 | CA2439528A1 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors |
| 09/26/2002 | CA2436911A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | CA2435847A1 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | CA2435825A1 New composition |
| 09/26/2002 | CA2435664A1 Ncc2705-the genome of a bifidobacterium |
| 09/26/2002 | CA2430619A1 Farnesyltransferase inhibitors |
| 09/26/2002 | CA2425902A1 Urocortin-iii and uses thereof |
| 09/25/2002 | EP1243648A1 Novel guanosine triphosphate-binding protein-coupled receptors, genes thereof and production and uses thereof |
| 09/25/2002 | EP1243583A1 Heterocyclic compounds having sulfonamide groups |
| 09/25/2002 | EP1243582A1 Quinoline and quinazoline derivatives and drugs containing the same |
| 09/25/2002 | EP1243581A1 Pyridinium compounds useful for the treatment of AGE-related diseases |
| 09/25/2002 | EP1243276A1 Elongated and multiple spacers containing activatible prodrugs |
| 09/25/2002 | EP1243274A2 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |